A pilot study of the clinical efficacy of platelet-rich plasma (PRP) for the treatment of endocrine therapy-induced alopecia (EIA) and permanent chemotherapy-induced alopecia (pCIA) in breast cancer patients.

富血小板血浆（PRP）治疗乳腺癌患者内分泌治疗引起的脱发（EIA）和永久性化疗引起的脱发（pCIA）临床疗效的初步研究。

• 批准号: 437123420
• 负责人: Dr. Christian Menzer
• 金额: --
• 依托单位: Division of Subspecialty Medicine
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2020
• 资助国家: 德国
• 起止时间: 2019-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/437123420?language=en
• 关键词: pilot; study; clinical; efficacy; platelet

Breast cancer is the most common cancer among women, with over 2 million new cases diagnosed worldwide in 2018. Modern therapies, consisting of chemotherapy and anti-hormonal therapy, are successfully used with a survival rate of greater than 80% in early stages. These anti-hormonal (endocrine) therapies are now recommended for as long as 5-10 years. Therefore, long-term side effects such as hair loss (alopecia) substantially compromise the quality of life in these patients. 8% of patients discontinue hormone therapy because of hair loss. Up to 25% suffer from hair loss because of the reduction of female hormones caused by the cancer treatment. Also, up to two thirds of patients treated with chemotherapy never fully grow back their hair afterwards. This can be a psychologically devastating event.Available treatments include minoxidil, a topical therapy that increases blood supply to the scalp, which has shown some improvement in hormone therapy-related hair loss, and the blood pressure medication spironolactone. There is, however, a need for further therapies for women who do not respond to minoxidil or spironolactone.Platelet Rich Plasma (PRP) was first used in orthopedic sports injuries to speed up recovery but has been increasingly used in dermatology for wound support, facial rejuvenation, and also hair loss. Platelets (thrombocytes) are a component of the blood that contains a high concentration of proteins with anti-inflammatory and growth-stimulating effects. PRP is obtained after blood centrifugation from the patient.In women with postmenopausal hair loss, PRP injections have shown a significant change in hair density and thickness even if the women had already received treatment with minoxidil or systemic therapy. Hair loss due to menopause resembles the cause of hair loss due to anti-hormonal therapy in cancer patients and suggests that PRP may be a suitable treatment for breast cancer patients suffering from this condition.In this pilot study, we want to treat breast cancer patients, who are experiencing hormone therapy- (EIA) and chemotherapy-related hair loss (pCIA), with PRP. 14 patients of each entity, EIA and pCIA, will be included. The patients will receive PRP injections on one half of their scalp whereas the other half of the scalp will not be treated, to serve as a study control. PRP is injected to the same half of the scalp once every 4 weeks for 12 weeks in a grid-like pattern. Treatment efficacy will be assessed at weeks 12 and 24 after the start of PRP. The effect on the quality of life will also be assessed. After 24 weeks, patients can cross over to a PRP treatment of the untreated side of their scalp if a benefit is seen.

乳腺癌是女性最常见的癌症，2018年全球新诊断病例超过200万例。现代治疗方法，包括化疗和抗激素治疗，在早期成功应用，存活率超过80%。这些抗激素(内分泌)疗法现在被推荐使用长达5-10年。因此，脱发(脱发)等长期副作用会严重影响这些患者的生活质量。8%的患者因脱发而停止激素治疗。多达25%的人因为癌症治疗导致的女性荷尔蒙减少而脱发。此外，多达三分之二的接受化疗的患者在接受化疗后从未完全长回头发。这可能是一个心理上的毁灭性事件。可用的治疗方法包括米诺地尔，一种增加头皮血液供应的局部疗法，它已经显示出与激素治疗相关的脱发的一些改善，以及降压药螺内酯。然而，对于对米诺地尔或螺内酯无效的女性，需要进一步的治疗。富含血小板血浆(PRP)最初用于骨科运动损伤以加快康复，但越来越多地被用于皮肤科，用于伤口支撑、面部年轻化和脱发。血小板是血液中的一种成分，含有高浓度的蛋白质，具有抗炎和刺激生长的作用。PRP是从患者的血液离心后获得的。在绝经后脱发的女性中，PRP注射显示出头发密度和厚度的显著变化，即使这些女性已经接受了米诺地尔或全身治疗。绝经导致的脱发与癌症患者抗激素治疗导致脱发的原因相似，这表明PRP可能是一种适合患有这种疾病的乳腺癌患者的治疗方法。在这项初步研究中，我们希望用PRP治疗正在接受激素治疗(EIA)和化疗相关脱发(PCIA)的乳腺癌患者。每个实体(EIA和pCIA)的14名患者将包括在内。患者将在其头皮的一半上接受PRP注射，而另一半头皮将不接受治疗，作为研究对照。PRP每4周注射到同一半头皮上，连续注射12周，形成网格状。治疗效果将在PRP开始后12周和24周进行评估。还将评估对生活质量的影响。24周后，如果看到疗效，患者可以过渡到对未治疗的一侧头皮进行PRP治疗。